Which patient populations were excluded from the PARADIGM trial comparing azacitidine-venetoclax to intensive chemotherapy?
Older patients over age 70
Patients with FLT3 mutations, core binding factor alterations, and younger patients with NPM1 mutations
All patients with adverse-risk cytogenetics